Linked Life Data

10069762

Source:http://linkedlifedata.com/resource/pubmed/id/10069762

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1999-6-1
pubmed:abstractText
Patients with cancer are at increased risk for thromboembolic disease. Commonly they present with abnormalities of one or more circulating markers of haemostatic system activation, underlying a 'hypercoagulable state'. Despite numerous investigations which have identified alterations in all of the haemostatic components (i.e. coagulation, fibrinolysis, endothelium, platelets and monocytes), no firm conclusions have been reached regarding the clinical utility of any of these coagulation markers for predicting thrombosis in cancer patients. The predictive value of one or more of these tests could help to identify safe and effective methods for prophylaxis against thrombotic complications in these patients. Plasma clotting abnormalities are usually exacerbated by chemotherapy. The mechanisms by which the haemostatic system is activated in malignancy (and chemotherapy) are reviewed.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0301-0147
pubmed:author
pubmed:issnType
Print
pubmed:volume
28 Suppl 3
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
50-60
pubmed:dateRevised
2005-11-16
pubmed:meshHeading
pubmed:year
1998
pubmed:articleTitle
Mechanisms of hypercoagulation in malignancy and during chemotherapy.
pubmed:affiliation
Haematology Division, Ospedali Riuniti, Bergamo, Italy.
pubmed:publicationType
Journal Article, Review